Current status in cellular-based therapies for prevention and treatment of COVID-19

References

• Coronavirus Resource Center [Internet]. Baltimore (MD): Johns Hopkins University; 2020-2022 [cited 2022 Nov 2]. Available from: https://coronavirus.jhu.edu/map.html
   Google Scholar
• Wu A, Peng Y, Huang B, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. 2020;27(3):325–328.
   PubMed Web of Science ®Google Scholar
• Huang Y, Yang C, Xu X-F, et al. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020;41(9):1141–1149.
   PubMed Web of Science ®Google Scholar
• Li H, Liu SM, Yu XH, et al. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents. 2020;55(5):105951.
   PubMed Web of Science ®Google Scholar
• Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–574.
   PubMed Web of Science ®Google Scholar
• Coronavirus (COVID 19) vaccinations- [Internet]. Oxford: Our World in Data; 2020–2022 [cited 2022. Jan 1]. Available from: https://ourworldindata.org/covid-vaccinations?country=OWID_WRL
   Google Scholar
• Kannan SR, Spratt AN, Sharma K, et al. Omicron SARS-CoV-2 variant: unique features and their impact on pre-existing antibodies. J Autoimmun. 2022;126:102779.
   PubMed Web of Science ®Google Scholar
• Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges, and recommendations. Nat Rev Drug Discov. 2019;18(1):41–58. ‏
   PubMed Web of Science ®Google Scholar
• Cancio M, Ciccocioppo R, Rocco P, et al. Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies. Cytotherapy. 2020;22(9):474–481.
   PubMed Web of Science ®Google Scholar
• Ou X, Liu Y, Lei X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11(1):1–12. ‏
   PubMed Web of Science ®Google Scholar
• Bestle D, Heindl MR, Limburg H, et al. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci Alliance. 2020;3(9):e202000786.
   PubMed Web of Science ®Google Scholar
• Lukassen S, Chua RL, Trefzer T, et al. SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. EMBO J. 2020;39(10):e105114.
   PubMed Web of Science ®Google Scholar
• Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(5):1036–1045.e9.
   PubMed Web of Science ®Google Scholar
• Broggi A, Granucci F, Zanoni I. Type III interferons: balancing tissue tolerance and resistance to pathogen invasion. J Exp Med. 2020;217(1):e20190295.
   PubMed Web of Science ®Google Scholar
• Broggi A, Ghosh S, Sposito B, et al. Type III interferons disrupt the lung epithelial barrier upon viral recognition. Science. 2020;369(6504):706–712.
   PubMed Web of Science ®Google Scholar
• Fung TS, Liu DX. Human coronavirus: host-pathogen interaction. Annu Rev Microbiol. 2019;73:529–557.
   PubMed Web of Science ®Google Scholar
• Martín-Vicente M, Resino S, Martínez I. Early innate immune response triggered by the human respiratory syncytial virus and its regulation by ubiquitination/deubiquitination processes. J Biomed Sci. 2022;29(1):11.
   PubMed Web of Science ®Google Scholar
• Tang Y, Liu J, Zhang D, et al. Cytokine storm in COVID-19: the current evidence and treatment strategies. Front Immunol. 2020;11:1708.
   PubMed Web of Science ®Google Scholar
• ‏Tay MZ, Poh CM, Rénia L, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363–374.
   PubMed Web of Science ®Google Scholar
• Coronavirus disease 2019 (COVID-19) treatment guidelines [Internet]. Windsor Mill (MD): US Department of Health and Human Services; [cited 2021 Nov 13]. Available from: https://www.covid19treatmentguidelines.nih.gov/
   Google Scholar
• van de Veerdonk FL, Giamarellos-Bourboulis E, Pickkers P, et al. A guide to immunotherapy for COVID-19. Nat Med. 2022;28(1):39–50.
   PubMed Web of Science ®Google Scholar
• Sposito B, Broggi A, Pandolfi L, et al. The interferon landscape along the respiratory tract impacts the severity of COVID-19. Cell. 2021;184(19):4953–4968.e16.
   PubMed Web of Science ®Google Scholar
• Clementi N, Ghosh S, De Santis M, et al. Viral respiratory pathogens and lung injury. Clin Microbiol Rev. 2021;34(3):e00103–e00120.
   Web of Science ®Google Scholar
• Galati D, Zanotta S, Capitelli L, et al. A bird’s eye view on the role of dendritic cells in SARS-CoV-2 infection: perspectives for immune-based vaccines. Allergy. 2022;77(1):100–110.
   PubMed Web of Science ®Google Scholar
• Collin M, Bigley V. Human dendritic cell subsets: an update. Immunology. 2018;154(1):3–20.
   PubMed Web of Science ®Google Scholar
• Kotenko SV, Rivera A, Parker D, et al. Type III IFNs: beyond antiviral protection. Semin Immunol. 2019;43:101303.
   PubMed Web of Science ®Google Scholar
• Harpur CM, Kato Y, Dewi ST, et al. Classical type 1 dendritic cells dominate priming of Th1 responses to herpes simplex virus type 1 skin infection. J Immunol. 2019;202(3):653–663.
   PubMed Web of Science ®Google Scholar
• Marzi A, Gramberg T, Simmons G, et al. DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus. J Virol. 2004;78(21):12090–12095.
   PubMed Web of Science ®Google Scholar
• Walls AC, Park YJ, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV- Spike glycoprotein. Cell. 2020;181(2):281–292.e6.
   PubMed Web of Science ®Google Scholar
• Carlin AF, Plummer EM, Vizcarra EA, et al. An IRF-3-, IRF-5-, and IRF-7-independent pathway of dengue viral resistance utilizes IRF-1 to stimulate type I and II interferon responses. Cell Rep. 2017;21(6):1600–1612.
   PubMed Web of Science ®Google Scholar
• Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422.
   PubMed Web of Science ®Google Scholar
• Law HKW, Cheung CY, Ng HY, et al. Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells. Blood. 2005;106(7):2366–2374.
   PubMed Web of Science ®Google Scholar
• Chu H, Zhou J, Wong BH, et al. Productive replication of Middle East respiratory syndrome coronavirus in monocyte-derived dendritic cells modulates innate immune response. Virology. 2014;:454–455:197–205.
   Google Scholar
• Han J, Sun J, Zhang G, et al. DCs-based therapies: potential strategies in severe SARS-CoV-2 infection. Int J Med Sci. 2021;18(2):406–418.
   PubMed Web of Science ®Google Scholar
• Yang D, Chu H, Hou Y, et al. Attenuated interferon and proinflammatory response in SARS-CoV-2-Infected human dendritic cells is associated with viral antagonism of STAT1 phosphorylation. J Infect Dis. 2020;222(5):734–745.
   PubMed Web of Science ®Google Scholar
• Zhou R, To KK, Wong YC, et al. Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses. Immunity. 2020;53(4):864.e5–877.e5.
   Web of Science ®Google Scholar
• Abel AM, Yang C, Thakar MS, et al. Natural killer cells: development, maturation, and clinical utilization. Front Immunol. 2018;9:1869.
   PubMed Web of Science ®Google Scholar
• Belizário JE, Neyra JM, Setúbal Destro Rodrigues MF. When and how NK cell-induced programmed cell death benefits immunological protection against intracellular pathogen infection. Innate Immun. 2018;24(8):452–465.
   PubMed Web of Science ®Google Scholar
• Schuster IS, Coudert JD, Andoniou CE, et al. “Natural regulators”: NK cells as modulators of T cell immunity. Front Immunol. 2016;14(7):235.
   Google Scholar
• Chan CJ, Smyth MJ, Martinet L. Molecular mechanisms of natural killer cell activation in response to cellular stress. Cell Death Differ. 2014;21(1):5–14.
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Netea MG, Rovina N, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. 2020;27(6):992.e3–1000.e3.
   Web of Science ®Google Scholar
• Diao B, Wang C, Tan Y, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. 2020;11:827.
   PubMed Web of Science ®Google Scholar
• Zheng M, Gao Y, Wang G, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533–535.
   PubMed Web of Science ®Google Scholar
• Wilk AJ, Rustagi A, Zhao NQ, et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat Med. 2020;26(7):1070–1076.
   PubMed Web of Science ®Google Scholar
• Lagunas-Rangel FA. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. J Med Virol. 2020;92(10):1733–1734.
   PubMed Web of Science ®Google Scholar
• Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, et al. SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020;54:62–75.
   PubMed Web of Science ®Google Scholar
• Braun J, Loyal L, Frentsch M, et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature. 2020;587(7833):270–274.
   PubMed Web of Science ®Google Scholar
• Chen Z, Wherry J. E. T cell responses in patients with COVID-19. Nat Rev Immunol. 2020;20(9):529–536.
   PubMed Web of Science ®Google Scholar
• Chiappelli F, Khakshooy A, Greenberg G. CoViD-19 immunopathology and immunotherapy. Bioinformation. 2020;16(3):219–222.
   PubMed Web of Science ®Google Scholar
• Zheng HY, Zhang M, Yang CX, et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol. 2020;17(5):541–543. ‏
   PubMed Web of Science ®Google Scholar
• Weiskopf D, Schmitz KS, Raadsen MP, et al. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci Immunol. 2020;5(48):eabd2071. ‏
   PubMed Web of Science ®Google Scholar
• Tan M, Liu Y, Zhou R, et al. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. Immunology. 2020;160(3):261–268.
   PubMed Web of Science ®Google Scholar
• Huang I, Pranata R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. J Intensive Care. 2020;8:36.
   PubMed Web of Science ®Google Scholar
• Chua RL, Lukassen S, Trump S, et al. COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis. Nat Biotechnol. 2020;38(8):970–979.
   PubMed Web of Science ®Google Scholar
• Regmi S, Pathak S, Kim JO, et al. Mesenchymal stem cell therapy for the treatment of inflammatory diseases: challenges, opportunities, and future perspectives. Eur J Cell Biol. 2019;98(5-8):151041.
   PubMed Web of Science ®Google Scholar
• Muraca M, Pessina A, Pozzobon M, et al. Mesenchymal stromal cells and their secreted extracellular vesicles as therapeutic tools for COVID-19 pneumonia? J Control Release. 2020;325:135–140.
   PubMed Web of Science ®Google Scholar
• Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11(2):216–228.
   PubMed Web of Science ®Google Scholar
• da Silva KN, Gobatto ALN, Costa-Ferro  , et al. Is there a place for mesenchymal stromal cell-based therapies in the therapeutic armamentarium against COVID-19? Stem Cell Res Ther. 2021;12:425.
   PubMed Web of Science ®Google Scholar
• Shao M, Xu Q, Wu Z, et al. Exosomes derived from human umbilical cord mesenchymal stem cells ameliorate IL-6-induced acute liver injury through miR-455-3p. Stem Cell Res Ther. 2020;11(1):1–13.
   PubMed Web of Science ®Google Scholar
• Xu YL, Liu YL, Wang Q, et al. Intravenous transplantation of mesenchymal stem cells attenuates oleic acid induced acute lung injury in rats. Chin Med J. 2012;125(11):2012–2018.
   PubMed Web of Science ®Google Scholar
• Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci. 2012;8(9):1237–1247.
   PubMed Web of Science ®Google Scholar
• Chen QH, Wu F, Liu L, et al. Mesenchymal stem cells regulate the Th17/Treg cell balance partly through hepatocyte growth factor in vitro. Stem Cell Res Ther. 2020;11(1):91.
   PubMed Web of Science ®Google Scholar
• Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal stem cells modulate B-cell functions. Blood. 2006;107(1):367–372.
   PubMed Web of Science ®Google Scholar
• Lu Z, Chang W, Meng S, et al. Mesenchymal stem cells induce dendritic cell immune tolerance via paracrine hepatocyte growth factor to alleviate acute lung injury. Stem Cell Res Ther. 2019;10(1):372.
   PubMed Web of Science ®Google Scholar
• Liu X, Qu X, Chen Y, et al. Mesenchymal stem/stromal cells induce the generation of novel IL-10-dependent regulatory dendritic cells by SOCS3 activation. J Immunol. 2012;189(3):1182–1192.
   PubMed Web of Science ®Google Scholar
• Yang Y, Hu S, Xu X, et al. The vascular endothelial growth factors-expressing character of mesenchymal stem cells plays a positive role in treatment of acute lung injury in vivo. Mediators Inflamm. 2016;2016:2347938.
   PubMed Web of Science ®Google Scholar
• Cahill EF, Kennelly H, Carty F, et al. Hepatocyte growth factor is required for mesenchymal stromal cell protection against bleomycin-Induced pulmonary fibrosis. Stem Cells Transl Med. 2016;5(10):1307–1318.
   PubMed Web of Science ®Google Scholar
• Alcayaga-Miranda F, Cuenca J, Khoury M. Antimicrobial activity of mesenchymal stem cells: current status and new perspectives of antimicrobial peptide-based therapies. Front Immunol. 2017;8:339.
   PubMed Web of Science ®Google Scholar
• Schwartz YS, Belogorodtsev SN, Filimonov PN, et al. BCG infection in mice is promoted by naïve mesenchymal stromal cells (MSC) and suppressed by poly(A: u)-conditioned MSC. Tuberculosis. 2016;101:130–136.
   PubMed Web of Science ®Google Scholar
• Foronjy RF, Dabo AJ, Cummins N, et al. Leukemia inhibitory factor protects the lung during respiratory syncytial viral infection. BMC Immunol. 2014;15:41.
   PubMed Web of Science ®Google Scholar
• Janssens K, Van den Haute C, Baekelandt V, et al. Leukemia inhibitory factor tips the immune balance towards regulatory T cells in multiple sclerosis. Brain Behav Immun. 2015;45:180–188.
   PubMed Web of Science ®Google Scholar
• Jafarzadeh A, Chauhan P, Saha B, et al. Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: lessons from SARS and MERS, and potential therapeutic interventions. Life Sci. 2020;257:118102.
   PubMed Web of Science ®Google Scholar
• Schulte-Schrepping J, Reusch N, Paclik D, et al. Severe COVID-19 is marked by a dysregulated myeloid cell compartment. Cell. 2020;182(6):1419–1440.e23.
   PubMed Web of Science ®Google Scholar
• Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20(6):355–362.
   PubMed Web of Science ®Google Scholar
• Saxena M, Bhardwaj N. Re-emergence of dendritic cell vaccines for cancer treatment. Trends Cancer. 2018;4(2):119–137.
   PubMed Web of Science ®Google Scholar
• Lineage cell therapeutics [Internet]. Carlsbad (CA): lineage Cell Therapeutics, Inc; 2021 [cited 2022 Mar 11]. Available from: https://lineagecell.com/products-pipeline/vac2/
   Google Scholar
• Bernhard H, Disis ML, Heimfeld S, et al. Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Res. 1995;55(5):1099–1104.
   PubMed Web of Science ®Google Scholar
• Balan S, Kale VP, Limaye LS. A simple two-step culture system for the large-scale generation of mature and functional dendritic cells from umbilical cord blood CD34+ cells. Transfusion. 2009;49(10):2109–2121.
   PubMed Web of Science ®Google Scholar
• Than UTT, Le HT, Hoang DH, et al. Induction of antitumor immunity by exosomes isolated from cryopreserved cord blood Monocyte-Derived dendritic cells. Int J Mol Sci. 2020;21(5):1834.
   PubMed Web of Science ®Google Scholar
• Waskow C, Liu K, Darrasse-Jèze G, et al. The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. Nat Immunol. 2008;9(6):676–683.
   PubMed Web of Science ®Google Scholar
• Leong JW, Chase JM, Romee R, et al. Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells. Biol Blood Marrow Transplant. 2014;20(4):463–473.
   PubMed Web of Science ®Google Scholar
• Sarvaria A, Jawdat D, Madrigal JA, et al. Umbilical cord blood natural killer cells, their characteristics, and potential clinical applications. Front Immunol. 2017;8:329.
   PubMed Web of Science ®Google Scholar
• Mu YX, Zhao YX, Li BY, et al. A simple method for in vitro preparation of natural killer cells from cord blood. BMC Biotechnol. 2019;19(1):80.
   PubMed Web of Science ®Google Scholar
• Knorr DA, Ni Z, Hermanson D, et al. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl Med. 2013;2(4):274–283.
   PubMed Web of Science ®Google Scholar
• Galat Y, Dambaeva S, Elcheva I, et al. Cytokine-free directed differentiation of human pluripotent stem cells efficiently produces hemogenic endothelium with lymphoid potential. Stem Cell Res Ther. 2017;8(1):67.
   PubMedGoogle Scholar
• Zeng J, Tang SY, Toh LL, et al. Generation of "off-the-Shelf" natural killer cells from peripheral blood cell-derived induced pluripotent stem cells. Stem Cell Rep. 2017;9(6):1796–1812.
   PubMed Web of Science ®Google Scholar
• Suck G, Odendahl M, Nowakowska P, et al. NK-92: an 'off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy. Cancer Immunol Immunother. 2016;65(4):485–492.
   PubMed Web of Science ®Google Scholar
• Caccamo N, Sullivan LC, Brooks AG, et al. Harnessing HLA-E-restricted CD8 T lymphocytes for adoptive cell therapy of patients with severe COVID-19. Br J Haematol. 2020;190(4):e185–e187.
   PubMed Web of Science ®Google Scholar
• Shah DK, Zúñiga-Pflücker JC. An overview of the intrathymic intricacies of T cell development. J Immunol. 2014;192(9):4017–4023.
   PubMed Web of Science ®Google Scholar
• Inoue H, Nagata N, Kurokawa H, et al. iPS cells: a game changer for future medicine. EMBO J. 2014;33(5):409–417.
   PubMed Web of Science ®Google Scholar
• Nishimura T, Kaneko S, Kawana-Tachikawa A, et al. Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell. 2013;12(1):114–126.
   PubMed Web of Science ®Google Scholar
• Phinney DG. Functional heterogeneity of mesenchymal stem cells: implications for cell therapy. J Cell Biochem. 2012;113(9):2806–2812.
   PubMed Web of Science ®Google Scholar
• Nagamura-Inoue T, He H. Umbilical cord-derived mesenchymal stem cells: their advantages and potential clinical utility. World J Stem Cells. 2014;6(2):195–202.
   PubMedGoogle Scholar
• Sanapati J, Manchikanti L, Atluri S, et al. Do regenerative medicine therapies provide long-term relief in chronic low back pain: a systematic review and metaanalysis. Pain Physician. 2018;21(6):515–540.
   PubMed Web of Science ®Google Scholar
• Routy JP, Boulassel MR, Yassine-Diab B, et al. Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin Immunol. 2010;134(2):140–147.
   PubMed Web of Science ®Google Scholar
• SARS-CoV-2 vaccine [Internet]. Irvine (CA): AIVITA Biomedical; 2020 [cited 2022 May 2022]. Available from: https://aivitabiomedical.com/programs/sars-cov-2/
   Google Scholar
• Aivita Biomedical, Inc. Adaptive phase I clinical trial of preventive vaccine consisting of autologous dendritic cells previously incubated with S-protein from SARS-CoV-2, in subjects negative for COVID-19 infection and anti-SARS-CoV-2 antibodies. ClinicalTrials.gov [Internet]. 2021 Dec 16 [cited 2022 May 15]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04690387
   Google Scholar
• Aivita Biomedical, Inc. Adaptive phase I-II clinical trial of preventive vaccine consisting of autologous dendritic cells previously incubated with S-protein from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), in subjects negative for COVID-19 infection and anti-SARS-CoV-2 antibodies. ClinicalTrials.gov [Internet]. 2021 Dec 16 [cited 2022 May 15]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04386252
   Google Scholar
• Shenzhen Geno-Immune Medical Institute. Phase I/II multicenter trial of lentiviral minigene vaccine (LV-SMENP) of covid-19 coronavirus. ClinicalTrials.gov [Internet]. 2020 Mar 19 [cited 2022 May 18]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04276896
   Google Scholar
• Rezvani K, Rouce R, Liu E, et al. Engineering natural killer cells for cancer immunotherapy. Mol Ther. 2017;25(8):1769–1781.
   PubMed Web of Science ®Google Scholar
• Liu E, Marin D, Banerjee P, et al. Use of CAR-transduced natural killer cells in CD19-Positive lymphoid tumors. N Engl J Med. 2020;382(6):545–553.
   PubMed Web of Science ®Google Scholar
• Daher M, Rezvani K. Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. Curr Opin Immunol. 2018;51:146–153.
   PubMed Web of Science ®Google Scholar
• Chongqing Public Health Medical Center. A phase I/II study of universal off-the-shelf NKG2D-ACE2 CAR-NK cells secreting IL15 superagonist and GM-CSF-neutralizing scFv for therapy of COVID-19. ClinicalTrials.gov [Internet]. 2020 Nov 17 [cited 2022 May 18]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04324996
   Google Scholar
• Tarrio ML, Lee SH, Fragoso MF, et al. Proliferation conditions promote intrinsic changes in NK cells for an IL-10 response. J Immunol. 2014;193(1):354–363.
   PubMed Web of Science ®Google Scholar
• Zheng G, Huang L, Tong H, et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respir Res. 2014;15(1):39.
   PubMedGoogle Scholar
• KK Women’s and Children’s Hospital. Part two of novel adoptive cellular therapy with SARS-CoV-2 specific T cells in patients with severe COVID-19. ClinicalTrials.gov [Internet]. 2020 July 7 [cited 2022 May 19]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04457726
   Google Scholar
• TC Biopharm. A phase II safety and tolerability, inter-patient pre-defined dose study of ex-vivo expanded allogeneic γδ T-lymphocytes (TCB008) in patients diagnosed with COVID-19. ClinicalTrials.gov [Internet]. 2022 Mar 24 [cited 2022 May 20]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04834128
   Google Scholar
• Mustafa Cetin, TC Erciyes University. Aerosol inhalation of the exosomes derived from allogenic COVID-19 T cell in the treatment of early stage novel coronavirus pneumonia. clinicalTrials.gov [Internet]. 2020 May 15 [cited 2022 May 20]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04389385
   Google Scholar
• Liang B, Chen J, Li T, et al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: a case report. Medicine. 2020;99(31):e21429.
   PubMed Web of Science ®Google Scholar
• Mahida RY, Matsumoto S, Matthay MA. Extracellular vesicles: a new frontier for research in acute respiratory distress syndrome. Am J Respir Cell Mol Biol. 2020;63(1):15–24.
   PubMed Web of Science ®Google Scholar
• Sengupta V, Sengupta S, Lazo A, et al. Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19. Stem Cells Dev. 2020;29(12):747–754.
   PubMed Web of Science ®Google Scholar
• Desai D, Shende P. Nanoconjugates-based stem cell therapy for the management of COVID-19. Stem Cell Rev Rep. 2021;17(1):231–240.
   PubMed Web of Science ®Google Scholar